Recombinant Human IL-13 R alpha 2 Fc Chimera (CHO), CF
Recombinant Human IL-13 R alpha 2 Fc Chimera (CHO), CF Summary
Product Specifications
| Human IL-13 R alpha 2 (Cys22-Leu342) Accession # NP_000631 |
IEGRMD | Human IgG1 (Pro100-Lys330) |
| N-terminus | C-terminus | |
Analysis
Product Datasheets
Carrier Free
CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.
In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.
7147-IR
| Formulation | Lyophilized from a 0.2 μm filtered solution in PBS. |
| Reconstitution | Reconstitute at 100 μg/mL in PBS. |
| Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
| Stability & Storage: | Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
Reconstitution Calculator
Background: IL-13 R alpha 2
Interleukin‑13 Receptor alpha 2 (IL‑13 R alpha 2), also known as IL‑13 binding protein, and CD213a2, is a widely expressed 55 kDa cytokine receptor that plays an important role in the Th2‑polarized immune responses characteristic of a variety of pathologies, including parasitic infections and allergic asthma (1, 2). Mature human IL‑13 R alpha 2 consists of a 317 amino acid (aa) extracellular domain with three fibronectin type‑III domains, a WSxWS motif, a 20 aa transmembrane segment, and a 17 aa cytoplasmic domain (3). Within the ECD, human IL‑13 R alpha 2 shares 64% and 62% aa sequence identity with mouse and rat IL‑13 R alpha 2, respectively. In both mouse and human, a 40 kDa‑50 kDa soluble form of IL‑13 R alpha 2 can be generated by MMP‑8 mediated shedding in vitro (4). Although this is assumed to occur in vivo in mouse, there is no evidence that shedding occurs in human (5‑7). In mouse, alternative splicing also leads to sIL‑13 R alpha 2, but again, this phenomenon apparently does not occur in human (6‑7). Thus, the biological effects of human IL‑13 R alpha 2 would appear to be mediated exclusively by membrane IL‑13 R alpha 2 (7). The biological effects of IL‑13 and IL‑4 are closely related in part due to a shared receptor system. IL‑13 binds to IL‑13 R alpha 1 which then forms a signaling complex with IL‑4 R alpha (8, 9). IL‑13 R alpha 2 functions as a decoy receptor by binding and internalizing IL‑13 and preventing it from signaling through the IL‑13 R alpha 1/IL‑4 R alpha complex (3, 10). IL‑13 R alpha 2 can also block IL‑4 induced responses by inhibiting IL‑4 bound IL‑13 R alpha 1/IL‑4 R alpha receptor complexes even though it does not itself bind IL‑4 (11, 12). Aside from its decoy function, IL‑13‑activated IL‑13 R alpha 2 directly promotes the development of tissue fibrosis by inducing the transcription of TGF‑ beta (13). Presumably, any human soluble IL‑13 R alpha 2, if it exists, will retain its ligand binding capability and attenuate responses to IL‑13 but not to IL‑4 (11, 14). The up‑regulation of transmembrane during Th2‑biased immune responses limits the extent of those responses (15‑17).
- Wynn, T.A. (2003) Annu. Rev. Immunol. 21:425.
- Tabata, Y. et al. (2007) Curr. Allergy Asthma Rep. 7:338.
- Caput, D. et al. (1996) J. Biol. Chem. 271:16921.
- Chen, W. et al. (2008) J. Allergy Clin. Immunol. 122:625.
- O’Toole, M. et al. (2008) Clin. Exp. Allergy 38:594.
- Chen, W. et al. (2009) J. Immunol. 183:7870.
- Kasaian, M.T. et al. (2011) J. Immunol. 187:561.
- Andrews, A.-L. et al. (2006) J. Immunol. 176:7456.
- Zurawski, S.M. et al. (1995) J. Biol. Chem. 270:13869.
- Donaldson, D.D. et al. (1998) J. Immunol. 161:2317.
- Andrews, A.-L. et al. (2006) J. Allergy Clin. Immunol. 118:858.
- Rahaman, S.O. et al. (2002) Cancer Res. 62:1103.
- Fichtner-Feigl, S. et al. (2006) Nat. Med. 12:99.
- Zhang, J.G. et al. (1997) J. Biol. Chem. 272:9474.
- Chiaramonte, M.G. et al. (2003) J. Exp. Med. 197:687.
- Morimoto, M. et al. (2009) J. Immunol. 183:1934.
- Zheng, T. et al. (2008) J. Immunol. 180:522.
Citations for Recombinant Human IL-13 R alpha 2 Fc Chimera (CHO), CF
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
7
Citations: Showing 1 - 7
Filter your results:
Filter by:
-
Intrathecal bivalent CAR T cells targeting EGFR and IL13R?2 in recurrent glioblastoma: phase 1 trial interim results
Authors: Bagley, SJ;Logun, M;Fraietta, JA;Wang, X;Desai, AS;Bagley, LJ;Nabavizadeh, A;Jarocha, D;Martins, R;Maloney, E;Lledo, L;Stein, C;Marshall, A;Leskowitz, R;Jadlowsky, JK;Christensen, S;Oner, BS;Plesa, G;Brennan, A;Gonzalez, V;Chen, F;Sun, Y;Gladney, W;Barrett, D;Nasrallah, MP;Hwang, WT;Ming, GL;Song, H;Siegel, DL;June, CH;Hexner, EO;Binder, ZA;O'Rourke, DM;
Nature medicine
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry -
Bi-Specific Killer Cell Engager Enhances NK Cell Activity against Interleukin-13 Receptor Alpha-2 Positive Gliomas
Authors: Pawlowski, KD;Duffy, JT;Tiwari, A;Zannikou, M;Balyasnikova, IV;
Cells
Species: Human
Sample Types: Protein
Applications: ELISA Capture -
Engineered IL13 variants direct specificity of IL13Ralpha2-targeted CAR T cell therapy
Authors: LA Stern, S Gholamin, I Moraga, X Yang, S Saravanaku, JR Cohen, R Starr, B Aguilar, V Salvary, JC Hibbard, A Kalbasi, JK Shepphird, J O'Hearn, KC Garcia, CE Brown
Proceedings of the National Academy of Sciences of the United States of America, 2022-08-08;119(33):e2112006119.
Species: Human
Sample Types: Whole Cell
Applications: Cell Culture -
Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma.
Authors: Bielamowicz K, Fousek K, Byrd T, Samaha H, Mukherjee M, Aware N, Wu M, Orange J, Sumazin P, Man T, Joseph S, Hegde M, Ahmed N
Neuro Oncol, 2018-03-27;20(4):506-518.
Species: Human
Sample Types: Whole Cells
Applications: CAR-T (Bioassay) -
Optimization of IL13R?2-Targeted Chimeric Antigen Receptor T Cells for Improved Anti-tumor Efficacy against Glioblastoma
Authors: CE Brown, B Aguilar, R Starr, X Yang, WC Chang, L Weng, B Chang, A Sarkissian, A Brito, JF Sanchez, JR Ostberg, M D'Apuzzo, B Badie, ME Barish, SJ Forman
Mol. Ther., 2017-10-05;26(1):31-44.
Species: Human
Sample Types: Whole Cells
Applications: Cell Culture -
Cytokine induction of VCAM-1 but not IL13Ralpha2 on glioma cells: a tale of two antibodies.
Authors: Mahadev V, Starr R, Wright S, Martinez C, Jensen M, Barish M, Forman S, Brown C
PLoS ONE, 2014-05-02;9(5):e95123.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma.
Authors: Hegde M, Corder A, Chow K, Mukherjee M, Ashoori A, Kew Y, Zhang Y, Baskin D, Merchant F, Brawley V, Byrd T, Krebs S, Wu M, Liu H, Heslop H, Gottschalk S, Yvon E, Ahmed N
Mol Ther, 2013-08-13;21(11):2087-101.
Species: Human
Sample Types: Whole Cells
Applications: CAR-T (Bioassay)
FAQs
No product specific FAQs exist for this product, however you may
View all Proteins and Enzyme FAQsReviews for Recombinant Human IL-13 R alpha 2 Fc Chimera (CHO), CF
Average Rating: 4 (Based on 1 Review)
Have you used Recombinant Human IL-13 R alpha 2 Fc Chimera (CHO), CF?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Filter by:
